Real-World Study Highlights Reduced Disability Progression of CIDP With Immunoglobulin Therapy
ANX005 Outperforms IVIg and Plasma Exchange in Improving Guillain-Barré Syndrome Outcomes
Outlining Phase 3 VITALIZE and MOBILIZE Trials of Riliprubart in CIDP: Luis Querol, MD, PhD
Rewiring Brain and Spine Tumor Care: AHN’s Coordinated, Personalized Approach